Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22246724 | 0.88 | PTGS1 (0.57) | PTGS1ESR1RXFP1MAPTKMT2A | |
| SCHEMBL22246769 | 0.87 | DHPS (0.43) | STING1AAK1SRCKMT2AMEN1 | |
| SCHEMBL22246677 | 0.86 | STING1 (0.51) | PTGS1STING1PARP1ESR1AAK1 | |
| SCHEMBL24214219 | 0.85 | STING1 (0.51) | STING1TRPV1NPC1RAB9A | |
| SCHEMBL30526943 | 0.85 | STING1 (0.51) | STING1TRPV1NPC1RAB9A | |
| SCHEMBL22246700 | 0.85 | KCNK2 (0.53) | STING1TRPV1NPC1LMNARAB9A | |
| SCHEMBL23167140 | 0.85 | STING1 (0.56) | STING1ESR1MAPTKMT2AMEN1 | |
| SCHEMBL24214130 | 0.85 | SMN1; SMN2 (0.44) | AAK1TRPV1MAPTKMT2AMEN1 | |
| SCHEMBL24214220 | 0.83 | LIPE (0.57) | NPC1LMNARAB9A | |
| SCHEMBL30526923 | 0.83 | LIPE (0.57) | NPC1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2023-04-06 | — | — | US | disclosed |
| WO-2022140397-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140403-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140410-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022140387-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020150417-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230106899-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | PTGS1 3104/4885STING1 1/4885PARP1 644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.